SEC Tracker
Get the app

Enanta Pharmaceuticals ENTA

Enanta Pharmaceuticals loses patent case

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. UPC ruled 265 Patent invalid
  2. Infringement action unfounded
  3. Pfizer counterclaimed for revocation
  4. Hearing held September 29, 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Enanta Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. TuHURA Biosciences HURA public float $111M, Jun 30, 2025
  2. Galectin Therapeutics GALT public float $109M, Jun 30, 2025
  3. Protara Therapeutics PRTO public float $112M, Jun 30, 2025
  4. Cartesian Therapeutics RNAC public float $109M, Jun 30, 2025
  5. Caribou Biosciences CRBU public float $113M, Jun 30, 2025